ERBB2 and non-small cell lung carcinoma: Though this real-world study precisely investigated the clinical activity of pyrotinib and afatinib for specific HER2 ex20ins variants in advanced NSCLC, as well as providing valuable evidence from molecular dynamics simulation and cellular kinase inhibition experiment, several limitations must be noted.